The University of Chicago Header Logo


Peter Riedell to Lymphoma, B-Cell

This is a "connection" page, showing publications Peter Riedell has written about Lymphoma, B-Cell.
Connection Strength

  1. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.
    View in: PubMed
    Score: 0.645
  2. Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969.
    View in: PubMed
    Score: 0.206
  3. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
    View in: PubMed
    Score: 0.205
  4. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
    View in: PubMed
    Score: 0.180
  5. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014 Jul; 13(7):977-87.
    View in: PubMed
    Score: 0.119
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.